NW-8-461 / Lupeng Pharma - LARVOL DELTA

Preclinical evaluation of a novel orally bioavailable MDM2 PROTAC, NW-8-461, in acute leukemia and myelofibrosis (AACR 2026) - "NW-8-461 exhibits markedly enhanced antiproliferative activity, demonstrating approximately 10-fold and 100-fold greater potency in cell viability assays compared with RG7388 and AMG232, respectively. In an orthotopic RS4; 11-Luc leukemia model, treatment with NW-8-461 at 25 mg/kg for 16 days resulted in complete eradication of leukemia cells in 7/7 mice and significantly superior efficacy compared with the MDM2 inhibitor RG7388. These results establish NW-8-461 as a differentiated and highly selective MDM2 degrader with strong therapeutic potential for p53-wild-type malignancies."

Late-breaking abstract • Preclinical • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • GSPT1 • IKZF1 • IKZF3 • MDM2 • SALL4